date:Nov 05, 2019
inal price of the product paid by consumers is modest, notes Koletzko.
He continues that expensive components are also added, including some probiotic bacterial strains. Some biotechnologically produced oligosaccharides may also be added. There is much less evidence for a benefit to the infant and hence, a much less favorable benefit to cost ratio. Koletzko hopes that manufacturers will not put formula based on a completely novel compositional concept on the market without accountable data tha